CA2210800A1 - Biopolymers derived from hydrolyzable diacid fats - Google Patents
Biopolymers derived from hydrolyzable diacid fatsInfo
- Publication number
- CA2210800A1 CA2210800A1 CA002210800A CA2210800A CA2210800A1 CA 2210800 A1 CA2210800 A1 CA 2210800A1 CA 002210800 A CA002210800 A CA 002210800A CA 2210800 A CA2210800 A CA 2210800A CA 2210800 A1 CA2210800 A1 CA 2210800A1
- Authority
- CA
- Canada
- Prior art keywords
- degradable bond
- derivative
- hydrolytically
- acid
- diacid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003925 fat Substances 0.000 title claims description 14
- 229920001222 biopolymer Polymers 0.000 title description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 39
- 239000000194 fatty acid Substances 0.000 claims abstract description 39
- 229930195729 fatty acid Natural products 0.000 claims abstract description 39
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 36
- 229920000642 polymer Polymers 0.000 claims description 56
- 239000003814 drug Substances 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 24
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 claims description 23
- 229960003656 ricinoleic acid Drugs 0.000 claims description 22
- 150000002148 esters Chemical class 0.000 claims description 13
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 12
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 11
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 claims description 10
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 10
- 239000004202 carbamide Substances 0.000 claims description 10
- 229920002732 Polyanhydride Polymers 0.000 claims description 9
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229920000728 polyester Polymers 0.000 claims description 7
- 230000015556 catabolic process Effects 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 229940114072 12-hydroxystearic acid Drugs 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- 229920002988 biodegradable polymer Polymers 0.000 claims description 4
- 239000004621 biodegradable polymer Substances 0.000 claims description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- SAIHVKCTLNFFQN-UHFFFAOYSA-N butanedioic acid;12-hydroxyoctadecanoic acid Chemical compound OC(=O)CCC(O)=O.CCCCCCC(O)CCCCCCCCCCC(O)=O SAIHVKCTLNFFQN-UHFFFAOYSA-N 0.000 claims description 2
- 230000000379 polymerizing effect Effects 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 1
- 230000008030 elimination Effects 0.000 abstract description 6
- 238000003379 elimination reaction Methods 0.000 abstract description 6
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 59
- 239000000178 monomer Substances 0.000 description 34
- WBHHMMIMDMUBKC-QJWNTBNXSA-N ricinoleic acid Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O WBHHMMIMDMUBKC-QJWNTBNXSA-N 0.000 description 20
- -1 poly(carboxyphenoxy propane) Polymers 0.000 description 19
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 229960003405 ciprofloxacin Drugs 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 208000031300 Hydrocephalus with stenosis of the aqueduct of Sylvius Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000026197 X-linked hydrocephalus with stenosis of the aqueduct of Sylvius Diseases 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000013456 study Methods 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 3
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- JVWMKVANCQIJBU-UHFFFAOYSA-N C(C=C/C(=O)O)(=O)O.OC(CCCCCCCCCCC(=O)O)CCCCCC Chemical compound C(C=C/C(=O)O)(=O)O.OC(CCCCCCCCCCC(=O)O)CCCCCC JVWMKVANCQIJBU-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 150000002905 orthoesters Chemical class 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- IGOIWSUDDYDHDR-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-hydroxyoctadecanoic acid Chemical compound OC(=O)\C=C/C(O)=O.CCCCCCCCCCCCCCCCC(O)C(O)=O IGOIWSUDDYDHDR-BTJKTKAUSA-N 0.000 description 1
- SBBLGUTVLYZMDS-UHFFFAOYSA-N 2,3-dihydroxy-2,3-dioctadecylbutanedioic acid Chemical compound CCCCCCCCCCCCCCCCCCC(O)(C(O)=O)C(O)(C(O)=O)CCCCCCCCCCCCCCCCCC SBBLGUTVLYZMDS-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- ODYCAZSSUVCHNU-XLAORIBOSA-N Laurencin Natural products CC[C@H]1C[C@H](CC=CC[C@@H]1Br)[C@@H](CC=CC#C)OC(=O)C ODYCAZSSUVCHNU-XLAORIBOSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RZLAESSFJYAXEY-UHFFFAOYSA-N butanedioic acid;2-hydroxyoctadecanoic acid Chemical compound OC(=O)CCC(O)=O.CCCCCCCCCCCCCCCCC(O)C(O)=O RZLAESSFJYAXEY-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940090046 jet injector Drugs 0.000 description 1
- 239000005367 kimax Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000008029 phthalate plasticizer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 238000006068 polycondensation reaction Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 239000002685 polymerization catalyst Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/96—Esters of carbonic or haloformic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/91—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/91—Polymers modified by chemical after-treatment
- C08G63/912—Polymers modified by chemical after-treatment derived from hydroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/44—Polyester-amides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2230/00—Compositions for preparing biodegradable polymers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
A monomeric diacid derivative includes at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond. In a biological environment, the bond degrades forming naturally occurring fatty acid products thereby allowing elimination.
Description
BTOpQLYM15R8 Dl!5RIVE:D FROI~ ~IYDROIIYZA.Bl~E DIACID FAT8 ~CENICA~ FIF~D
This invention relates to the area of organic synthesis and, in particular, the synthesis of biocompatible polymers.
0 R~PO~ND OF T~S INV~N~ON
Over the last 20 years, many classes of biodegradable polymers have been under development for a wide variety of biomedical applications.l The most actively pursued biomaterials include: the lactide/glycolide copolymers, polyorthoesters, polycaprolactones, polyphosphazenes and polyanhydrides.l~2~3 One of the widely studied application~ of these polymers is their use in implantable drug delivery systems. For this application, polyanhydrides are a unique class of polymers because some of them demonstrate a near zero order drug release and a relatively rapid biodegradation in vivo.
Some of the desired physico-chemical and mechanical properties in a single polymer that could be used in an implantable or injectable drug delivery system are:
a. hydrophobic enough so that the drug is released in a predictable and controlled way;
b. biocompatible when implanted in the target organ;
c. being completely eliminated from the implantation site in a predictable time;
d. suitable physical properties for device fabrication properties (low melting point, usually below 100~C, and soluble in common organic solvents);
e. flexible enough before and during degradation so that it does not crumble or fragment during use;
and f. easy to manufacture at a reasonable cost.
Some of these ideal properties are displayed by some of the polyanhydrides. For example, poly(carboxyphenoxy propane) ~PtCPP)] displays near zero order erosion and release kinetics.~ However, this polymer displays an extremely slow degradation rate, and it is estimated that a drug delivery device prepared from P(CPP) would take almost three years to completely degrade in vivo.
In U.S. Patent 5,171,812, a class of aliphatic copolyanhydrides was synthesized from dimers and trimers of unsaturated fatty acids (FAD and FAT, respectively) with sebacic acid. This class of polymers were demonstrated to have the properties suitable for developing various types of implantable drug delivery devices, including:
microspheres, films, rods, and beads.
In a recent publication,5 a class of aliphatic copolyanhydrides was synthesized from nonlinear hydrophobic S dimers (FAD) of erucic acid and sebacic acid (SA). This class had some biocompatible characteristics even though there was a rapid partial degradation within the first ten days with the release of the SA component, a residue which i8 mostly the FAD comonomer remains and is not easily degraded.
Although these polymers were found suitable for drug delivery applications both in vivo and in vitro, studies in dogs showed that when implanted in muscle, the polymer degraded to the synthetic fatty acid dimer which was not eliminated from the implantation site even after six month~. This semisynthQtic fatty acid dimer is not easily metab~lized in the body because it contains a non-natural structure of a C-C bridge (Structure 1) which is difficult to be metabolized by body enzymes.
8tructur~ atty ac~d D~ -r HOOC ----~ ~,~ ~ , ,COOH
2s WO 96)22270 PCT~5~
The FAD and related oligomers of fatty acids are the coupling products of two or more unsaturated fatty acids in which the original fatty acids are connected via a chemically stable C-C bond (non-hydrolyzable). Because the oligomerized fatty acids contain a non-natural structure (C-C branching points), they may not be eliminated at the same rate and capacity as natural fatty acids, which are readily eliminated from the body by a ~-oxidation process.
8~NMARY OF T~ lNV~10~ aND ADVANTAG~8 According to the present invention, a monomeric diacid derivative comprising at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond is formed. In a biological environment, the bond degrades forming naturally occurring fatty acid products thereby allowing elimination.
In general, the monomeric diacid derivative has the structure H
Rl--C--R--COOH
'2-COOH
wherein R, R1 and R2 are aliphatic organic residues with 0 to 20 carbon atoms and can be the same or different, S is an enzymatically or hydrolytically degradable bond selected from the group consisting of ester, amide, urethane, acetal, urea, and carbonate bonds can be formed.
WO 96/22270 PCTm~95/00007 - The absence of stable C-C nonhydroyzable branching bonds allows these monomers to be first hydrolyzed to the respective natural acids and then rapidly eliminated since naturally occurring fatty acids are formed and are readily eliminated from the body via ~-oxidation.
BRIEF D28CRIPTION OF TB DRA~ING8 Other advantages of the present invention will be readily appreciated as the same becomes better understood lo by reference to the following detailed description when considered in connection with the accompanying drawings wherein:
FIGURE 1 is a graph showing hydrolytic degradation of polymers based on ricinoleic acid as determined by weight loss and conversion of anhydride to acid groups, degradation being determined in 0.1M phosphate buffer pH 7.4 at 37~C;
FIGURE 2 is a graph showing in vitro release of ciprofloxacin from ricinoleic acid maleate-based polymeric devices, drug release being determined in 0.lM phosphate buffer pH 7.4 at 37~C; and FIGURE 3 is a graph showing in vitro release of ciprofloxacin from ricinoleic acid maleate-sebacic acid copolymer based polymeric devices, drug release being determined in 0.lM phosphate buffer pH 7.4 at 37~C.
WO 96122270 PCT~IB95/00007 DETAI~ED DE8CRlPTION OF TB PR~F~RRED EMBODIMENT
The present invention relates to biodegradable polymers containing novel hydrolyzable diacid fats which provide hydrophobicity and improved physical and mechanical properties to the polymers as compared to biopolymers that do not contain these monomeric units, and yet are completely degradable to natural products when exposed to biological environments.
In searching for an alternative hydrophobic monomer that possesses similar properties to the FAD but is more readily eliminated from the body, i.e. does not contain a stable C-C coupling bond, applicants have synthesized a new class of fatty-acid-based-diacid monomers with similar properties to the FAD monomer but that hydrolyze to the natural fatty acid.
The diacids were synthesized from fatty acids containing a hydroxyl or amine side group and aliphatic diacid derivatives. The general structure of these monomers is:
H
Rl--C--R--COOH
wherein R, Rl and R2 are aliphatic organic residues with 0 to 20 carbon atoms and can be the same or different, S is an enzymatically or hydrolytically degradable bond selected WO 96122270 PCT/l~SJ~007 - from the group consisting of ester, amide, urethane, acetal, urea, or carbonate bonds can be formed. Examples of other useful monomers are diacid derivatives of tartaric acid and glycerylmonostearate.
These monomers are synthesized, for example, from natural hydroxy fatty acids which are reacted with dicarboxylic acid derivatives, such as cyclic anhydrides, to provide diacid monomers suitable for anhydride and ester polymerization. The reaction is conducted in an organic solvent where the hydroxy acid is reacted under reflux with the cyclic anhydride. When other reactive acids are used, the reaction conditions should be adjusted. The natural molecules are therefore linked by an hydrolyzable bond which include: ester, amide, imide, orthoester, carbonate, urethane, urea or phosphate ester. These diacid fats can be polymerized or copolymerized into a polyanhydride or polyester and form polymers that are, in general, of a low melting point (below 100~C), soluble in common organic solvents, and pliable materials.
This invention is demonstrated by the synthesis and characterization of polymers based on ricinoleic acid.
Natural hydroxy fatty acids, such as 12-hydroxy stearic acid and ricinoleic acid were reacted with cyclic anhydrides such as succinic or maleic anhydride, to provide diacid monomers suitable for anhydride and ester polymerization. These monomers are expected to degrade in WO 96122270 PCTIIB95~00007 vivo into their fatty acid and succinic acid counterparts since they are bound by a hydrolyzable ester bond.
The structures of the diacids are:
1. Ricinoleic ~cid m~le~te (RAhI) CH
o ,.
c=o o II. 1'-Hydroxysteanc acid succinate (~SAS) '~ r~~ ~
III. 12-Hydroxystearic acid maleate (HSAM) a~
Diacids were synthesized based on Ricinoleic acid, 12-hydroxy oleic acid. The hydroxyl group was reacted with maleic anhydride to form ricinoleic acid maleate (I). Hydrogenolysis of this diacid forms the saturated derivative, 12-hydroxy stearic acid succinate (II). A third diacid monomer was synthesized from the W096/22270 PCT/~55Jo0007 reaction between 12-hydroxy stearic acid and maleic anhydride (III). These diacid monomers were incorporated into a polyanhydride or polyester and used as carriers for drugs.
The diacid fats used a~ examples in this application have the following general structures:
8tructur- 2. Naturally occurring f~tty ac~
co~t~ining ~i~ci~ uonom-r~
A. monogfycsridQ dica~boxyfic acid CH2-O-CO-(CH2)X-CH3 ICH2--~Z (CH2)jCOOH
HOOC(CH2)yZ~cH2 B. Ta~taric ac~d diafkyl derivative COOH
CH O-Z- (C~)x~C~3 CHb-(CH~x-Z~o CH
COOH
C. Oicarbox~ic acid fat CH3 (CH2~v ICH (C~)W--COOH
M
(CH2)~,- COOH
WO 96122270 PCT11~s55/00007 where: x-5-25; y=1-12; v+w=25; Z=CO,C0-O,CO-NH; and M=O-CO, O-CO-O, O-CO-NH, O-P02-0, NH-CO.
These monomers are diacid derivatives of monoglycerides, tartaric acid and fatty acids having an additional functional group with one or more natural molecules linked by an hydrolyzable bond which include:
ester, amide, imide, orthoester, carbonate, urethane, urea or phosphate ester. These diacid fats can be polymerized or copolymerized into a polyanhydride or polyester and form polymers that are, in general, of a low melting point (below 100~C), soluble in common organic solvents, and pliable materials that are useful in making biodegradable medical devices. For example, microspheres loaded with drugs can be prepared for the delivery of drugs in vivo and in vitro. Because these monomers hydrolyze in a biological environment to their o~iginal natural and safe counterparts, they are biocompatible and their elimination time after polymer degradation is within three months.
These monomers are polymerized into polyanhydrides and into polyesters as described in the examples.
Additionally, these diacid fats can be used as plasticizing components in plastics such as nylon, polyurethane as substitute for oligomerized fatty acids with the advantage of simple structure and ease of preparation.
WO 96/22270 PCT/lb5S/'l,l~D07 The present invention allows the preparation of a drug release system which will deliver a pharmacologically effective amount of a drug. The drug is held or entrapped in a polymer matrix. The matrix essentially consists of repeating units of a monomeric diacid derivative comprising at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond whereby said degradable bond in a biological environment degrades forming naturally occurring fatty acid lo products. As the bonds degrade the drug is released. The bonds can be ester, amide, urethane, urea and carbonate bonds.
The drugs in solid form are melted or dispersed in the polymer to form a matrix, small molecules, as well as large molecules, such as peptides, proteins, and antibodies, can be delivered from the polymer matrix. The duration of drug release is mostly affected by the hydrophobicity of the drug, drug loading, and polymer composition.
Further, the present invention can be used as a biocompatible, biodegradable, implantable material essentially consisting of repeating units of a monomeric diacid derivative comprising at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond whereby said degradable bond in a biological environment degrades forming naturally occurring fatty acid WO 96J22270 PCT/1~95/000~17 products. The bonds can be ester, amide, urethane, urea and carbonate bonds. The implantable material can be used to form dressings, sutures and the like that need to be implanted but not remain in the body. For example, they can be used as films for surgical adhesion prevention by placing the polymer film at the abraded area during surgery.
In general, the method for synthesizing the biodegradable polymer containing hydrolyzable diacid fats requires the preparation of at least one highly pure prepolymer of monomeric diacid derivative comprising at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond. The prepolymer is then polymerized at a temperature and reaction time to form a polyanhydride or polyester of an appropriate molecular weight. The polymerization is stopped when a molecular weight between 10,000 and 100,000 is obtained for the needed application or device.
A copolymer is formed from at least two highly pure prepolymers polymerized together as described above.
U.S. Patent 4,757,128 to Domb et al., issued July 1988, discloses examples of classes of monomers that can be copolymerized with the monomers of the present invention to form copolyanhydrides. Typical and useful co-monomers are the aliphatic diacid such as adipic, subernic, dodedecane dicarboxylic acid. Other co-monomers can be iso-phthalic WO 96/22270 PCT/lbSSlC~007 - acid, terephthalic acid, carboxphenoxypropane. The copolymer of RAM with subernic acid gave a Mw of 32,000, the copolymer with iso-phthalic acid gave a Mw of 24,000.
The ricinoleic acid maleate of the present invention are useful as plasticizer for plastic modeling.
The following is the preferred method of preparing the formulation.
Ricinoleic acid maleate containinq ~lasticizer Low volatile polyester mixtures based on Ricinoleic acid maleate are useful as plasticizer for plastic modeling:
A mixture of adipic acid (58 grams), ricinoleic acid maleate (7 grams), propylene glycol (38 grams), and n-hexanol (13 grams) was heated at 140~C for five hours while water was distilled. To the reaction mixture, 0.05% of stannous octoate was added as catalyst and the reaction temperature was increased to 180~C and a vacuum of 0.1 mm Hg waa applied for an additional three hours. The resulting viscous polymer had a molecular weight of 700 as determined by gel permeation chromatography. The resulting oligomer was mixed 30 weight percent with polyvinylchloride (PVC) to form a flexible sheet which had a loss of 0.5 weight percent in the volatility test at 105~C for three days compared to 1.2 to 2.5% with the phthalate plasticizer. Other plasticizers were prepared similarly w~s6l22270 PCTnB9S/00007 using hydroxy stearic acid succinate or hydroxy stearic acid maleate instead of ricinoleic acid maleate.
Preparation of hydrophilic plasticizer:
Ricinoleic acid maleate was reacted with two equivalents of poly(ethylene glycol) MW~ 2,000 in toluene with 1% H3PO4 (85% concentration) as catalyst. ~he reaction was continued for five hours at 110~C. Toluene was eva~orated to dryness to form an oily material. The material was mixed in PVC to form a flexible sheet which had a loss of .6% at 105~C for three days volatility test.
The following examples illustrate the preparation of and use of the monomers and polymers of the present invention:
Materials and Methods The following compounds were used: ricinoleic acid (Kodak 91% pure), maleic anhydride (BDH, 99.5%), Sebacic acid (Aldrich 99%), acetic anhydride, toluene (dried by azeotropic distillation before use), EtOH (abs.), CH2C12, and CHC13 (all Frutarom analytical grade).
IR spectroscopy was performed on an Analect Instruments FTIR spectrometer model fx-6160 using a Data system MAP-67. Monomer, prepolymer, and polymer samples were film cast onto NaCl plates or dissolved in chloroform and placed in a NaCl cell.
Ultraviolet spectroscopy was performed on a Kontron~ Instruments Uvikon spectrophotometer model 930.
WO 96/22270 PCTlIli9~ )7 - Melting points were determined on an Electrothermal melting point apparatus. Melt transition temperatures and degree of crystallinity were determined by a Perkin Elmer DSC 7 differential scAnning calorimeter, calibrated with zinc and indium standards. The heating rate was 20~C/min for all the polymers, under nitrogen atmosphere.
Molecular weights of the polymers and prepolymers were estimated on a GPC system composed of a Spectra 10Physics P1000 pump, Applied Biosystems 759A Absorbance UV
detector at 254 nm, Spectra Physics Data Jet injector, and a WINner/286 data analysis computer system. Samples were eluted in dichloromethane through a linear Styroget, 104 A
pore size, at a flow rate of 1 ml/min and monitored at 254 lS nm. Molecular weight of polymers were determined relative to polystyrene st~n~Ards (Polysciences, PA), with a molecular weight range of 400 to l,S00,000 using Maxima 840 computer program (Waters, MA).
lH-NMR spectra were obtained on a Varian 300 MHz spectrometer at 23~C using deuterated chloroformtTMS
solvent. Chemical shifts were expressed in ppm downfield from Me4Si as an internal stAn~Ard. The values are given in d scale.
Tensile strength measurements were attained using an Instron Tensile Tester Model 1114 at room temperature.
WO 96/22270 PCT)IB95100007 Catalytic hydrogenation was performed using 3% Pd on activated carbon (Aldrich) using a Parr apparatus.
Evaporation's were carried out on a Buchi RE 111 Rotavapor.
~m~les 1. ~onomer and Polymor Rynthesi~
Ricinoleic acid maleate (RAM). A solution of ricinoleic acid (144 g, 0.48 mol) and maleic anhydride (61 g, 0.61 mol) in toluene (350 ml) was stirred at 80-sooc overnight. The excess of maleic anhydride which precipitated was removed by filtration. The solution was washed four times with distilled water, dried over MgSO4 and evaporated to dryness to give 140.92 g (73%) of product as a dark orange oil. Titration (using THF as solvent and phenolphthalein as indicator) with 0.1 N NaOH showed 88%
diacid product; IR 1740, 1715 cm~l; lH-NMR 6.33 (dd, 2H, HOOC-C~=C~-COO-), S.45 (m, lH, C-C~=CH-C), 5.28 (m, lH, C-CH=C~-C), 5.00 (quintet, lH, methine), 2.33 (m, 2H, C~2-COOH), 2.00 (dd, 2H, OCO-C-C~2-CH=CH), 1.60 (m, 4H, C~2-CH2-COOH and COO-CH-C~2-CH2), 1.25 (broad d, 18H, aliphatic methylenes), 0.83 (t, 3H, -CH3) t 2-hydroxysteric acid succinate (HSAS). A
solution of RAM (50 g. 0.13 mol) in abs. EtOH (- 100 ml) was hydrogenated over 3 g Pd/C at 85 atm overnight. The catalyst was filtered off, and the solution was evaporated to dryness yielding 46.83 g (94%) of an oily orange liquid, which upon cooling to room temperature solidified to an CA 022l0800 l997-07-l7 WO 96/22270 PCTllkg5/00007 off- white solid which was dissolved in hot EtOH and left to recrystallize in the freezer for two weeks. The product was filtered and dried to give 37.0 g (74%), mp 50-52~C; IR
1740, 1715 cm~l; lH-NMR 4.88 (quintet, lH, methine), 2.77 (t, 2H, HOCO-C~2-CH2-COO-CH), 2.63 (t, 2H, HOCO-CH2-Ca2-COO-CH), 2.42 (t, 2H, C~2-COOH), 1.62 (m, 4H, C~2-CH-OCO-CH2), 1.52 (m, 2H, C~2-CH2-COOCO), 1.23 (m, 22H, aliphatic methylenes), 0.85 (t, 3~, C~2-CH3) 12-hydroxystearic acid maleate rHSA~). A
solution of ricinoleic acid (50 g, 0.17 mol) in abs. EtOH
(-100 ml) was hydrogenated over 3 g Pd/C at 80 atm overnight. The solidified product was dissolved in CH2Cl2, and the catalyst was removed by filtration. The solution was evaporated yielding 50 g (100%) of product.
Recrystallization from EtOH gave 35.0 g (70%). The FTIR
and NMR spectra were similar to those described in the Aldrich 93 catalogs, mp 73-75~C (lit: Aldrich 93 catalog 80-81~C). A solution of 12-hydroxystearic acid (34.45 g, 0.11 mol) and maleic anhydride (14.5 g, 0.148 mol) in toluene (240 ml) was stirred at 88~C overnight. The solution was washed four times with distilled water, dried over MgSO4 and evaporated to dryness to yield 40.0 g (88%). Titration (using THF as solvent and phenolphthalein as indicator) with 0.1 N NaOH showed 96%
diacid product; IR 1740, 1715 cm 1; lH-NMR 6.38 (d, 2H, COCH=C~CO), 5.02 (t, lH, C~OCO), 2.36 (t, 2H, C~2COOH), 1.61 WO 96/22270 PCT/1~>95/00007 (m, 6H, ~2CCOCHO and C~2CH2COOH), 1.27 (m, 22H, (CH2)ll), 0.88 (t,3H,C~3)-Preparation of prepolymers. The prepolymers of sebacic acid (SA) were prepared as previously described. 6 Briefly, sebacic acid prepolymer was prepared from the purified diacid monomer by refluxing it in excess acetic anhydride for 30 minutes and evaporating it to dryness.
The hot clear viscous residue was dissolved in dichloromethane and the prepolymer was precipitated in a lo mixture of hexane/isopropyl ether (1:1). The solid was collected by filtration and dried by vacuum at room temperature.
Prepolymers of the fatty acid ester based monomers were prepared as follows: Solutions of each monomer dissolved in acetic anhydride (120~C, 1:5 w/v) were stirred under reflux for 20 min.
The RAM prepolymer solution was evaporated to drynes~ to give an orange oil product. Mw-3800 Mn-3520; IR
2900, 2850, 1810, 1720 cm~l; lH-NMR 6.30 (dd, 2H, CO-CH=CH-CO), 5.42 (d, lH, CH=CH), 5.38 (d, lH, CH=C~), 4.98 (quintet, lH, methine), 2.45 (t, 2H when prepolymer is head-to-tail, CH2-COO-), 2.40 (t, 2H when prepolymer is head-to-head, CH2-COO-), 2.32 (s, 3H, C~3-COOCO-CH=CH), 2.21 (s, 3H, CH3-COOCO-CH2-CH2), 2.00 (dd, 2H, C-C~2-CH=CH), 2.30 (m, 2H, CH=CH-CH2-CH2-) 1.60 (m, 4H, C~2- CH2-COOCO- and CH=CH-COO-CH-CX2-CH2), 1.30 (broad d, 16H, aliphatic methylenes), 0.87 (t, 3H, CH2-C~3). The HSAS prepolymer gave a semisolid off-white product. Mw-1788 Mn-1382; IR
2900, 2850 1820, 1730 cm~l; lH-NMR 4.88 (quintet, lH, methine), 2.77 (t, 2H, COOCO-C~2-CH2-COO-CH), 2.65 (t, 2H, COOCO-CH2-C~2-COO-CH), 2.44 (t, 2H, C~2-COOCO), 1.65 (m, 4H, CR2-CH-OCO-CH2), 1.55 (quintet, 2H, CR2- CH2-C0OCO) 1.25 (m, 22H, aliphatic methylenes), 0.85 (t, 3H, CH2-CH3).
The HSAM prepolymer gave a viscous oil. Mw-1788 Mn-1382; IR 2900, 2850, 1820, 1730 cm~l, lH- NMR 6.26 (dd, 2H, CO-CH=CH-CO), ~.92 (quintet, lH, methine), 2.47 (t, 2H
when prepolymer is head-to-tail, CH2-COO-), 2.40 (t, 2H when prepolymer is head-to-head, CH2-C0O-), 2.25 (s, 3H, C~3-COOCO-CH=CH), 2.17 (s, 3H, C~3-COOCO-CH2-CH2), 1.52 (m, 4H, CX2-CH2-COOCO- and CH=CH-COO-CH-C~2-CH2), 1.21 (broad, d, 22H, aliphatic methylenes), 0.83 (t, 3H, C~2-CH3).
Pre~aration of polymers. The prepolymers underwent melt polycondensation. Typically, RAM prepolymer (10 g, 33 mmol) was placed in a KIMAX~ glass tube with a side arm or a round bottomed flask and polymerized at 180~C
under reduced pressure (0.1-0.5 mm Hg). The polymerization was complete after 90 minutes. The by-products, acetic anhydride and acetic acid, were trapped in a liquid N2 trap.
The homopolymers were viscous yellow oils.
- Copolymers were prepared similarly by polymerizing a mixture of prepolymers at 180~C under reduced pres~ure. In a typical experiment, RAM prepolymer (5 g, 17 mmol) was mixed with sebacic acid prepolymer (SA-diAc) (5 g, 21 mmol) and polymerized at 180~C under reduced pressure for 60-90 minutes depending on the amount being polymerized. The crude polymers were dissolved in CH2C12 (1.5 w/v) and filtered into stirring di-isopropyl ether (100-200 ml). The precipitate was separated by filtration, washed with di-isopropyl ether, and dried in the Rotavapor.
Molecular weights and thermal characterization of the polymers are shown in Table 1. The IR and lH-NMR
of homopolymers of RAM,HSAM,HSAS, and 1:1 copolymers with SA (d ppm) are listed in Table 2.
Mechanical ProDerties. These series of polymers had similar mechanical properties to the FAD class of polymers. They formed very flexible films with similar strength as seen in Table 3.
This invention relates to the area of organic synthesis and, in particular, the synthesis of biocompatible polymers.
0 R~PO~ND OF T~S INV~N~ON
Over the last 20 years, many classes of biodegradable polymers have been under development for a wide variety of biomedical applications.l The most actively pursued biomaterials include: the lactide/glycolide copolymers, polyorthoesters, polycaprolactones, polyphosphazenes and polyanhydrides.l~2~3 One of the widely studied application~ of these polymers is their use in implantable drug delivery systems. For this application, polyanhydrides are a unique class of polymers because some of them demonstrate a near zero order drug release and a relatively rapid biodegradation in vivo.
Some of the desired physico-chemical and mechanical properties in a single polymer that could be used in an implantable or injectable drug delivery system are:
a. hydrophobic enough so that the drug is released in a predictable and controlled way;
b. biocompatible when implanted in the target organ;
c. being completely eliminated from the implantation site in a predictable time;
d. suitable physical properties for device fabrication properties (low melting point, usually below 100~C, and soluble in common organic solvents);
e. flexible enough before and during degradation so that it does not crumble or fragment during use;
and f. easy to manufacture at a reasonable cost.
Some of these ideal properties are displayed by some of the polyanhydrides. For example, poly(carboxyphenoxy propane) ~PtCPP)] displays near zero order erosion and release kinetics.~ However, this polymer displays an extremely slow degradation rate, and it is estimated that a drug delivery device prepared from P(CPP) would take almost three years to completely degrade in vivo.
In U.S. Patent 5,171,812, a class of aliphatic copolyanhydrides was synthesized from dimers and trimers of unsaturated fatty acids (FAD and FAT, respectively) with sebacic acid. This class of polymers were demonstrated to have the properties suitable for developing various types of implantable drug delivery devices, including:
microspheres, films, rods, and beads.
In a recent publication,5 a class of aliphatic copolyanhydrides was synthesized from nonlinear hydrophobic S dimers (FAD) of erucic acid and sebacic acid (SA). This class had some biocompatible characteristics even though there was a rapid partial degradation within the first ten days with the release of the SA component, a residue which i8 mostly the FAD comonomer remains and is not easily degraded.
Although these polymers were found suitable for drug delivery applications both in vivo and in vitro, studies in dogs showed that when implanted in muscle, the polymer degraded to the synthetic fatty acid dimer which was not eliminated from the implantation site even after six month~. This semisynthQtic fatty acid dimer is not easily metab~lized in the body because it contains a non-natural structure of a C-C bridge (Structure 1) which is difficult to be metabolized by body enzymes.
8tructur~ atty ac~d D~ -r HOOC ----~ ~,~ ~ , ,COOH
2s WO 96)22270 PCT~5~
The FAD and related oligomers of fatty acids are the coupling products of two or more unsaturated fatty acids in which the original fatty acids are connected via a chemically stable C-C bond (non-hydrolyzable). Because the oligomerized fatty acids contain a non-natural structure (C-C branching points), they may not be eliminated at the same rate and capacity as natural fatty acids, which are readily eliminated from the body by a ~-oxidation process.
8~NMARY OF T~ lNV~10~ aND ADVANTAG~8 According to the present invention, a monomeric diacid derivative comprising at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond is formed. In a biological environment, the bond degrades forming naturally occurring fatty acid products thereby allowing elimination.
In general, the monomeric diacid derivative has the structure H
Rl--C--R--COOH
'2-COOH
wherein R, R1 and R2 are aliphatic organic residues with 0 to 20 carbon atoms and can be the same or different, S is an enzymatically or hydrolytically degradable bond selected from the group consisting of ester, amide, urethane, acetal, urea, and carbonate bonds can be formed.
WO 96/22270 PCTm~95/00007 - The absence of stable C-C nonhydroyzable branching bonds allows these monomers to be first hydrolyzed to the respective natural acids and then rapidly eliminated since naturally occurring fatty acids are formed and are readily eliminated from the body via ~-oxidation.
BRIEF D28CRIPTION OF TB DRA~ING8 Other advantages of the present invention will be readily appreciated as the same becomes better understood lo by reference to the following detailed description when considered in connection with the accompanying drawings wherein:
FIGURE 1 is a graph showing hydrolytic degradation of polymers based on ricinoleic acid as determined by weight loss and conversion of anhydride to acid groups, degradation being determined in 0.1M phosphate buffer pH 7.4 at 37~C;
FIGURE 2 is a graph showing in vitro release of ciprofloxacin from ricinoleic acid maleate-based polymeric devices, drug release being determined in 0.lM phosphate buffer pH 7.4 at 37~C; and FIGURE 3 is a graph showing in vitro release of ciprofloxacin from ricinoleic acid maleate-sebacic acid copolymer based polymeric devices, drug release being determined in 0.lM phosphate buffer pH 7.4 at 37~C.
WO 96122270 PCT~IB95/00007 DETAI~ED DE8CRlPTION OF TB PR~F~RRED EMBODIMENT
The present invention relates to biodegradable polymers containing novel hydrolyzable diacid fats which provide hydrophobicity and improved physical and mechanical properties to the polymers as compared to biopolymers that do not contain these monomeric units, and yet are completely degradable to natural products when exposed to biological environments.
In searching for an alternative hydrophobic monomer that possesses similar properties to the FAD but is more readily eliminated from the body, i.e. does not contain a stable C-C coupling bond, applicants have synthesized a new class of fatty-acid-based-diacid monomers with similar properties to the FAD monomer but that hydrolyze to the natural fatty acid.
The diacids were synthesized from fatty acids containing a hydroxyl or amine side group and aliphatic diacid derivatives. The general structure of these monomers is:
H
Rl--C--R--COOH
wherein R, Rl and R2 are aliphatic organic residues with 0 to 20 carbon atoms and can be the same or different, S is an enzymatically or hydrolytically degradable bond selected WO 96122270 PCT/l~SJ~007 - from the group consisting of ester, amide, urethane, acetal, urea, or carbonate bonds can be formed. Examples of other useful monomers are diacid derivatives of tartaric acid and glycerylmonostearate.
These monomers are synthesized, for example, from natural hydroxy fatty acids which are reacted with dicarboxylic acid derivatives, such as cyclic anhydrides, to provide diacid monomers suitable for anhydride and ester polymerization. The reaction is conducted in an organic solvent where the hydroxy acid is reacted under reflux with the cyclic anhydride. When other reactive acids are used, the reaction conditions should be adjusted. The natural molecules are therefore linked by an hydrolyzable bond which include: ester, amide, imide, orthoester, carbonate, urethane, urea or phosphate ester. These diacid fats can be polymerized or copolymerized into a polyanhydride or polyester and form polymers that are, in general, of a low melting point (below 100~C), soluble in common organic solvents, and pliable materials.
This invention is demonstrated by the synthesis and characterization of polymers based on ricinoleic acid.
Natural hydroxy fatty acids, such as 12-hydroxy stearic acid and ricinoleic acid were reacted with cyclic anhydrides such as succinic or maleic anhydride, to provide diacid monomers suitable for anhydride and ester polymerization. These monomers are expected to degrade in WO 96122270 PCTIIB95~00007 vivo into their fatty acid and succinic acid counterparts since they are bound by a hydrolyzable ester bond.
The structures of the diacids are:
1. Ricinoleic ~cid m~le~te (RAhI) CH
o ,.
c=o o II. 1'-Hydroxysteanc acid succinate (~SAS) '~ r~~ ~
III. 12-Hydroxystearic acid maleate (HSAM) a~
Diacids were synthesized based on Ricinoleic acid, 12-hydroxy oleic acid. The hydroxyl group was reacted with maleic anhydride to form ricinoleic acid maleate (I). Hydrogenolysis of this diacid forms the saturated derivative, 12-hydroxy stearic acid succinate (II). A third diacid monomer was synthesized from the W096/22270 PCT/~55Jo0007 reaction between 12-hydroxy stearic acid and maleic anhydride (III). These diacid monomers were incorporated into a polyanhydride or polyester and used as carriers for drugs.
The diacid fats used a~ examples in this application have the following general structures:
8tructur- 2. Naturally occurring f~tty ac~
co~t~ining ~i~ci~ uonom-r~
A. monogfycsridQ dica~boxyfic acid CH2-O-CO-(CH2)X-CH3 ICH2--~Z (CH2)jCOOH
HOOC(CH2)yZ~cH2 B. Ta~taric ac~d diafkyl derivative COOH
CH O-Z- (C~)x~C~3 CHb-(CH~x-Z~o CH
COOH
C. Oicarbox~ic acid fat CH3 (CH2~v ICH (C~)W--COOH
M
(CH2)~,- COOH
WO 96122270 PCT11~s55/00007 where: x-5-25; y=1-12; v+w=25; Z=CO,C0-O,CO-NH; and M=O-CO, O-CO-O, O-CO-NH, O-P02-0, NH-CO.
These monomers are diacid derivatives of monoglycerides, tartaric acid and fatty acids having an additional functional group with one or more natural molecules linked by an hydrolyzable bond which include:
ester, amide, imide, orthoester, carbonate, urethane, urea or phosphate ester. These diacid fats can be polymerized or copolymerized into a polyanhydride or polyester and form polymers that are, in general, of a low melting point (below 100~C), soluble in common organic solvents, and pliable materials that are useful in making biodegradable medical devices. For example, microspheres loaded with drugs can be prepared for the delivery of drugs in vivo and in vitro. Because these monomers hydrolyze in a biological environment to their o~iginal natural and safe counterparts, they are biocompatible and their elimination time after polymer degradation is within three months.
These monomers are polymerized into polyanhydrides and into polyesters as described in the examples.
Additionally, these diacid fats can be used as plasticizing components in plastics such as nylon, polyurethane as substitute for oligomerized fatty acids with the advantage of simple structure and ease of preparation.
WO 96/22270 PCT/lb5S/'l,l~D07 The present invention allows the preparation of a drug release system which will deliver a pharmacologically effective amount of a drug. The drug is held or entrapped in a polymer matrix. The matrix essentially consists of repeating units of a monomeric diacid derivative comprising at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond whereby said degradable bond in a biological environment degrades forming naturally occurring fatty acid lo products. As the bonds degrade the drug is released. The bonds can be ester, amide, urethane, urea and carbonate bonds.
The drugs in solid form are melted or dispersed in the polymer to form a matrix, small molecules, as well as large molecules, such as peptides, proteins, and antibodies, can be delivered from the polymer matrix. The duration of drug release is mostly affected by the hydrophobicity of the drug, drug loading, and polymer composition.
Further, the present invention can be used as a biocompatible, biodegradable, implantable material essentially consisting of repeating units of a monomeric diacid derivative comprising at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond whereby said degradable bond in a biological environment degrades forming naturally occurring fatty acid WO 96J22270 PCT/1~95/000~17 products. The bonds can be ester, amide, urethane, urea and carbonate bonds. The implantable material can be used to form dressings, sutures and the like that need to be implanted but not remain in the body. For example, they can be used as films for surgical adhesion prevention by placing the polymer film at the abraded area during surgery.
In general, the method for synthesizing the biodegradable polymer containing hydrolyzable diacid fats requires the preparation of at least one highly pure prepolymer of monomeric diacid derivative comprising at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond. The prepolymer is then polymerized at a temperature and reaction time to form a polyanhydride or polyester of an appropriate molecular weight. The polymerization is stopped when a molecular weight between 10,000 and 100,000 is obtained for the needed application or device.
A copolymer is formed from at least two highly pure prepolymers polymerized together as described above.
U.S. Patent 4,757,128 to Domb et al., issued July 1988, discloses examples of classes of monomers that can be copolymerized with the monomers of the present invention to form copolyanhydrides. Typical and useful co-monomers are the aliphatic diacid such as adipic, subernic, dodedecane dicarboxylic acid. Other co-monomers can be iso-phthalic WO 96/22270 PCT/lbSSlC~007 - acid, terephthalic acid, carboxphenoxypropane. The copolymer of RAM with subernic acid gave a Mw of 32,000, the copolymer with iso-phthalic acid gave a Mw of 24,000.
The ricinoleic acid maleate of the present invention are useful as plasticizer for plastic modeling.
The following is the preferred method of preparing the formulation.
Ricinoleic acid maleate containinq ~lasticizer Low volatile polyester mixtures based on Ricinoleic acid maleate are useful as plasticizer for plastic modeling:
A mixture of adipic acid (58 grams), ricinoleic acid maleate (7 grams), propylene glycol (38 grams), and n-hexanol (13 grams) was heated at 140~C for five hours while water was distilled. To the reaction mixture, 0.05% of stannous octoate was added as catalyst and the reaction temperature was increased to 180~C and a vacuum of 0.1 mm Hg waa applied for an additional three hours. The resulting viscous polymer had a molecular weight of 700 as determined by gel permeation chromatography. The resulting oligomer was mixed 30 weight percent with polyvinylchloride (PVC) to form a flexible sheet which had a loss of 0.5 weight percent in the volatility test at 105~C for three days compared to 1.2 to 2.5% with the phthalate plasticizer. Other plasticizers were prepared similarly w~s6l22270 PCTnB9S/00007 using hydroxy stearic acid succinate or hydroxy stearic acid maleate instead of ricinoleic acid maleate.
Preparation of hydrophilic plasticizer:
Ricinoleic acid maleate was reacted with two equivalents of poly(ethylene glycol) MW~ 2,000 in toluene with 1% H3PO4 (85% concentration) as catalyst. ~he reaction was continued for five hours at 110~C. Toluene was eva~orated to dryness to form an oily material. The material was mixed in PVC to form a flexible sheet which had a loss of .6% at 105~C for three days volatility test.
The following examples illustrate the preparation of and use of the monomers and polymers of the present invention:
Materials and Methods The following compounds were used: ricinoleic acid (Kodak 91% pure), maleic anhydride (BDH, 99.5%), Sebacic acid (Aldrich 99%), acetic anhydride, toluene (dried by azeotropic distillation before use), EtOH (abs.), CH2C12, and CHC13 (all Frutarom analytical grade).
IR spectroscopy was performed on an Analect Instruments FTIR spectrometer model fx-6160 using a Data system MAP-67. Monomer, prepolymer, and polymer samples were film cast onto NaCl plates or dissolved in chloroform and placed in a NaCl cell.
Ultraviolet spectroscopy was performed on a Kontron~ Instruments Uvikon spectrophotometer model 930.
WO 96/22270 PCTlIli9~ )7 - Melting points were determined on an Electrothermal melting point apparatus. Melt transition temperatures and degree of crystallinity were determined by a Perkin Elmer DSC 7 differential scAnning calorimeter, calibrated with zinc and indium standards. The heating rate was 20~C/min for all the polymers, under nitrogen atmosphere.
Molecular weights of the polymers and prepolymers were estimated on a GPC system composed of a Spectra 10Physics P1000 pump, Applied Biosystems 759A Absorbance UV
detector at 254 nm, Spectra Physics Data Jet injector, and a WINner/286 data analysis computer system. Samples were eluted in dichloromethane through a linear Styroget, 104 A
pore size, at a flow rate of 1 ml/min and monitored at 254 lS nm. Molecular weight of polymers were determined relative to polystyrene st~n~Ards (Polysciences, PA), with a molecular weight range of 400 to l,S00,000 using Maxima 840 computer program (Waters, MA).
lH-NMR spectra were obtained on a Varian 300 MHz spectrometer at 23~C using deuterated chloroformtTMS
solvent. Chemical shifts were expressed in ppm downfield from Me4Si as an internal stAn~Ard. The values are given in d scale.
Tensile strength measurements were attained using an Instron Tensile Tester Model 1114 at room temperature.
WO 96/22270 PCT)IB95100007 Catalytic hydrogenation was performed using 3% Pd on activated carbon (Aldrich) using a Parr apparatus.
Evaporation's were carried out on a Buchi RE 111 Rotavapor.
~m~les 1. ~onomer and Polymor Rynthesi~
Ricinoleic acid maleate (RAM). A solution of ricinoleic acid (144 g, 0.48 mol) and maleic anhydride (61 g, 0.61 mol) in toluene (350 ml) was stirred at 80-sooc overnight. The excess of maleic anhydride which precipitated was removed by filtration. The solution was washed four times with distilled water, dried over MgSO4 and evaporated to dryness to give 140.92 g (73%) of product as a dark orange oil. Titration (using THF as solvent and phenolphthalein as indicator) with 0.1 N NaOH showed 88%
diacid product; IR 1740, 1715 cm~l; lH-NMR 6.33 (dd, 2H, HOOC-C~=C~-COO-), S.45 (m, lH, C-C~=CH-C), 5.28 (m, lH, C-CH=C~-C), 5.00 (quintet, lH, methine), 2.33 (m, 2H, C~2-COOH), 2.00 (dd, 2H, OCO-C-C~2-CH=CH), 1.60 (m, 4H, C~2-CH2-COOH and COO-CH-C~2-CH2), 1.25 (broad d, 18H, aliphatic methylenes), 0.83 (t, 3H, -CH3) t 2-hydroxysteric acid succinate (HSAS). A
solution of RAM (50 g. 0.13 mol) in abs. EtOH (- 100 ml) was hydrogenated over 3 g Pd/C at 85 atm overnight. The catalyst was filtered off, and the solution was evaporated to dryness yielding 46.83 g (94%) of an oily orange liquid, which upon cooling to room temperature solidified to an CA 022l0800 l997-07-l7 WO 96/22270 PCTllkg5/00007 off- white solid which was dissolved in hot EtOH and left to recrystallize in the freezer for two weeks. The product was filtered and dried to give 37.0 g (74%), mp 50-52~C; IR
1740, 1715 cm~l; lH-NMR 4.88 (quintet, lH, methine), 2.77 (t, 2H, HOCO-C~2-CH2-COO-CH), 2.63 (t, 2H, HOCO-CH2-Ca2-COO-CH), 2.42 (t, 2H, C~2-COOH), 1.62 (m, 4H, C~2-CH-OCO-CH2), 1.52 (m, 2H, C~2-CH2-COOCO), 1.23 (m, 22H, aliphatic methylenes), 0.85 (t, 3~, C~2-CH3) 12-hydroxystearic acid maleate rHSA~). A
solution of ricinoleic acid (50 g, 0.17 mol) in abs. EtOH
(-100 ml) was hydrogenated over 3 g Pd/C at 80 atm overnight. The solidified product was dissolved in CH2Cl2, and the catalyst was removed by filtration. The solution was evaporated yielding 50 g (100%) of product.
Recrystallization from EtOH gave 35.0 g (70%). The FTIR
and NMR spectra were similar to those described in the Aldrich 93 catalogs, mp 73-75~C (lit: Aldrich 93 catalog 80-81~C). A solution of 12-hydroxystearic acid (34.45 g, 0.11 mol) and maleic anhydride (14.5 g, 0.148 mol) in toluene (240 ml) was stirred at 88~C overnight. The solution was washed four times with distilled water, dried over MgSO4 and evaporated to dryness to yield 40.0 g (88%). Titration (using THF as solvent and phenolphthalein as indicator) with 0.1 N NaOH showed 96%
diacid product; IR 1740, 1715 cm 1; lH-NMR 6.38 (d, 2H, COCH=C~CO), 5.02 (t, lH, C~OCO), 2.36 (t, 2H, C~2COOH), 1.61 WO 96/22270 PCT/1~>95/00007 (m, 6H, ~2CCOCHO and C~2CH2COOH), 1.27 (m, 22H, (CH2)ll), 0.88 (t,3H,C~3)-Preparation of prepolymers. The prepolymers of sebacic acid (SA) were prepared as previously described. 6 Briefly, sebacic acid prepolymer was prepared from the purified diacid monomer by refluxing it in excess acetic anhydride for 30 minutes and evaporating it to dryness.
The hot clear viscous residue was dissolved in dichloromethane and the prepolymer was precipitated in a lo mixture of hexane/isopropyl ether (1:1). The solid was collected by filtration and dried by vacuum at room temperature.
Prepolymers of the fatty acid ester based monomers were prepared as follows: Solutions of each monomer dissolved in acetic anhydride (120~C, 1:5 w/v) were stirred under reflux for 20 min.
The RAM prepolymer solution was evaporated to drynes~ to give an orange oil product. Mw-3800 Mn-3520; IR
2900, 2850, 1810, 1720 cm~l; lH-NMR 6.30 (dd, 2H, CO-CH=CH-CO), 5.42 (d, lH, CH=CH), 5.38 (d, lH, CH=C~), 4.98 (quintet, lH, methine), 2.45 (t, 2H when prepolymer is head-to-tail, CH2-COO-), 2.40 (t, 2H when prepolymer is head-to-head, CH2-COO-), 2.32 (s, 3H, C~3-COOCO-CH=CH), 2.21 (s, 3H, CH3-COOCO-CH2-CH2), 2.00 (dd, 2H, C-C~2-CH=CH), 2.30 (m, 2H, CH=CH-CH2-CH2-) 1.60 (m, 4H, C~2- CH2-COOCO- and CH=CH-COO-CH-CX2-CH2), 1.30 (broad d, 16H, aliphatic methylenes), 0.87 (t, 3H, CH2-C~3). The HSAS prepolymer gave a semisolid off-white product. Mw-1788 Mn-1382; IR
2900, 2850 1820, 1730 cm~l; lH-NMR 4.88 (quintet, lH, methine), 2.77 (t, 2H, COOCO-C~2-CH2-COO-CH), 2.65 (t, 2H, COOCO-CH2-C~2-COO-CH), 2.44 (t, 2H, C~2-COOCO), 1.65 (m, 4H, CR2-CH-OCO-CH2), 1.55 (quintet, 2H, CR2- CH2-C0OCO) 1.25 (m, 22H, aliphatic methylenes), 0.85 (t, 3H, CH2-CH3).
The HSAM prepolymer gave a viscous oil. Mw-1788 Mn-1382; IR 2900, 2850, 1820, 1730 cm~l, lH- NMR 6.26 (dd, 2H, CO-CH=CH-CO), ~.92 (quintet, lH, methine), 2.47 (t, 2H
when prepolymer is head-to-tail, CH2-COO-), 2.40 (t, 2H when prepolymer is head-to-head, CH2-C0O-), 2.25 (s, 3H, C~3-COOCO-CH=CH), 2.17 (s, 3H, C~3-COOCO-CH2-CH2), 1.52 (m, 4H, CX2-CH2-COOCO- and CH=CH-COO-CH-C~2-CH2), 1.21 (broad, d, 22H, aliphatic methylenes), 0.83 (t, 3H, C~2-CH3).
Pre~aration of polymers. The prepolymers underwent melt polycondensation. Typically, RAM prepolymer (10 g, 33 mmol) was placed in a KIMAX~ glass tube with a side arm or a round bottomed flask and polymerized at 180~C
under reduced pressure (0.1-0.5 mm Hg). The polymerization was complete after 90 minutes. The by-products, acetic anhydride and acetic acid, were trapped in a liquid N2 trap.
The homopolymers were viscous yellow oils.
- Copolymers were prepared similarly by polymerizing a mixture of prepolymers at 180~C under reduced pres~ure. In a typical experiment, RAM prepolymer (5 g, 17 mmol) was mixed with sebacic acid prepolymer (SA-diAc) (5 g, 21 mmol) and polymerized at 180~C under reduced pressure for 60-90 minutes depending on the amount being polymerized. The crude polymers were dissolved in CH2C12 (1.5 w/v) and filtered into stirring di-isopropyl ether (100-200 ml). The precipitate was separated by filtration, washed with di-isopropyl ether, and dried in the Rotavapor.
Molecular weights and thermal characterization of the polymers are shown in Table 1. The IR and lH-NMR
of homopolymers of RAM,HSAM,HSAS, and 1:1 copolymers with SA (d ppm) are listed in Table 2.
Mechanical ProDerties. These series of polymers had similar mechanical properties to the FAD class of polymers. They formed very flexible films with similar strength as seen in Table 3.
2. ~ynth~ of poly--t-rs conta~n~ng fatty diac$d monom-rs. Biodegradable polyesters were synthesized from the reaction between lactide, ricinoleic acid maleate, and propylene glycol in the molar ratio 8:1:1 and 1% stannous octoate as polymerization catalyst. The mixture of the monomers were polymerized at 100~C under nitrogen with constant stirring. After 24 hours, the temperature was raised to 140~C, the reaction was continued for another 24 hours and then a vacuum of 0.1 mm Hg was applied and the reaction was continued for another 8 hours.
The viscous melt was solidified into a pliable tan mass.
Polymers containing HSAM and HSAS monomers at various ratios were prepared similarly. The data analysis of these polymers is summarized in Table 4. All polymers were soluble in dichloromethane, chloroform, and tetrahydrofuran. IR spectra of the polymers showed esters peaks at 1720 nm.
The viscous melt was solidified into a pliable tan mass.
Polymers containing HSAM and HSAS monomers at various ratios were prepared similarly. The data analysis of these polymers is summarized in Table 4. All polymers were soluble in dichloromethane, chloroform, and tetrahydrofuran. IR spectra of the polymers showed esters peaks at 1720 nm.
3. 8ynthesis of d~st-aryl tartaric acid. Into a flask were placed 100 ml dichlomethane, tartaric acid (0.1 mole), triethylamine (0.4 mole), and stearoyl chloride (0.2 mole). The reaction was left for 24 hours with constant stirring. The reaction mixture was washed with o.lN HCl solution to yield distearyl tartaric acid.
4. In vivo biocompatibility and elimination studi-J. The biocompatibility and the elimination time of these new polymers as compared to poly(FAD-SA)50:50 and poly(sebacic acid) {PSA} was studied in rats as follows:
Clean specimens (30 mg, 2x2x4 mm in size) of the following polymers:
1. poly(RAM-SA)30:70, 2. poly (HSAM - SA) 50: 50, 3. poly(HSAS-SA)50:50, 4. poly(FAD-SA)50:50, 5. Vicril (Ethicon), 6. poly(FAD-SA)50:50, and 7. poly(sebacic acid) {PSA}
WO 96S22270 PCT/lb551~0007 were implanted subcutaneously in four dorsal sites of male Sprague-Dawley rats (250-300 g). Six rats were used in the study and each rat was implanted randomly with four different specimens. All animal work was done under sterile conditions. The polymer specimens were dipped in 70% alcohol prior to insertion. The animals were sacrificed after 12 and 30 days post implantation, and the implantation sites were examined macroscopically and histologically. The polymer remnants were retrieved and analyzed.
Macroscopically, no swelling or pathological signs were observed in any of the groups during the experiment and at sacrifice. The animals appeared healthy and did not show any weight loss. The implantation sites were clean and normal without any swelling and the remnants of the implanted polymers were easily retrieved. At the implant site of the new polymers, a small amount of polymer remnants (30-40% of the original mass) in the form of a soft mass was seen. The animals implanted with poly(FAD-SA)50:50 had solid remnants in the site of about 70~ of the original implant size. About 20% of the PSA remained at the implant site after 12 days, and the Vicril polymer remained intact. Histopathology examination of tissue specimens from the area confined to the tissue in direct 2S contact with the polymer device showed mild inflammation which was rated 2 in a scale from 1 to 5 where: 1 -PCT111~3100007 resembles no irritation; 2 - slight inflammation; 3 -moderate; 4 - marked; and 5 - severe inflammation. No encapsulation was found with any of the samples.
A second group of rats which were implanted with the polymers under similar conditions were completely eliminated from the site after 12 weeks. In comparison, Vicril polymers remained almost intact, poly(FAD-sA)so:5o was only 60% eliminated.
This experiment indicates that the new fatty acid based polymers are biocompatible. The elimination time in vivo of these polymers is shorter than for the FAD-based polymers.
The rat model has been considered highly predictable of human response for toxicant elimination7 and biocompatibility. 8 5. In vitro hydrolysis. The hydrolysis of the l:1 copolymers with SA was studied by:
(a) weight loss of the sample;
(b) monitorinq the change of molecular weight by gel permeation chromatograph (GPC);
(c) monitoring the disappearance of the anhydride linkage and the formation of carboxylic acid by FTIR
spectroscopy; and (d) the release of sebacic acid from the polymer by HPLC analysis.
The hydrolysis studies were conducted in 0.1 M
phosphate buffer pH 7.4 at 37~C using rectangular samples 3x5x8 mm in size and weighing about 100-150 mg. The samples were taken out from the buffer at different time intervals and were weighed after being dried thoroughly in the oven. The percent weight loss of the sample and the transformation of the anhydride bond to acid as a function of time are shown in Figure 1. The change in molecular weight was monitored by GPC showing a drastic drop in molecular weight in the first 24 hours and then stabilized at about 6,000-7,000 from then on. The samples were observed visually for the changes in the external appearance. At any stage of the experiment, the samples did not crumble nor were there any cracks visible.
6. In vi~o ~n~ymat~c degradat~on. The enzymatic degradation of these new monomers were compared to those of the oligomerized fatty acids. The monomers RAM, HSAM, HSAS, FAD, and FAT (200 mg) were mixed in a solution containing esterase (2 ml, containing 50 units of esterase from porcine liver, Sigma Chemical Company, St.
Louis, Missouri) and were incubated for 24 hours at 37~C.
The monomers or their degradation products were extracted with chloroform and analyzed by lH NMR. The lH NMR spectra of the FAD and FAT monomers were identical before and after treatment. The RAM, and HSAS monomers contained about 10%
ricinoleic acid or 12-hydroxy stearic acid, respectively.
WO 96/22270 PCT/~5S,'0~û~7 This study demonstrates the biodegradability of the new monomers compared to the oligomerized fatty acid monomers.
7. In vitro drug r-leas-. Ciprofloxacin (5% by weight) was incorporated in rectangular tablets (3x5x8 mm in size and 200 mg weight) of poly(RAM-SA)l:l, P(HSAM:SA)l:l, P(HSAS:SA)l:l, P(FAD:SA)1:1 and poly(suberic anhydride) by the melt method. In vitro drug release was determined in phosphate buffer pH 7.4 at 37~C.
Ciprofloxacin concentration was determined by W detection at 272 nm. The results are shown in Figure 2. The drug release followed a first order kinetics (r2=0.89-0.99) with a fast release during the first lO days and a slow release thereafter.
In a second experiment, Ciprofloxacin (5% weight) was incorporated in rectangular tablets (3x5x8 mm in size and 20 mg weight) of poly(RAM-SA) of various compositions by the melt method. In vitro drug release was determined in phosphate buffer pH 7.4 at 37~C. Ciprofloxacin concentration was determined by W detection at 272 nm.
The results are shown in Figure 3. The drug release followed a first order kinetics (r2=0.96) with a fast release during the first 10 days and a slow release thereafter. The drug release rate was increased with the increase in the sebacic acid content in the polymer;
however, a small difference in the release profile was found for the polymers composed of 40 to 80% sebacic acid WC)96122270 PCT/lb9S~ ~7 (SA). Similar results were reported for the FAD-SA
copolymers.
The preparation of dimer oleic acid or dimer erucic acid (FAD) contains two steps. In the first step, oleic acid or erucic acid undergo a coupling reaction using clay as a catalyst. In the second step, the product is hydrogenated to saturate the double bonds in the product.
During the first step, many by-products are formed, including trimers and tetramers, that are difficult to remove. Also, the FAD product contains cyclic and aromatic by-products which counts to about 30% of the Priipol 1004 and lOo9 products which are the most available pure FAD
products (based on producer, Unicema, information). The product of the present invention contains only one component, the linear diacid monomer which is synthesized in a single esterification step (condensation reaction in general) which cannot form other oligomers or cyclic materials, but the linear diacid as described herein.
The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.
Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims the invention may be practiced otherwise than as specifically described.
PCTIIB9~/00007 W~ 96122270 T~ Mol-cul~r ~-~g~t~ ~nd th~ l ch~ract-r~ation o~ f~tty aci~ ~-t-r pol~-r~
Polym~r of Molecular weiBhtMel~ing pointb TmC ~d Mw Mn (~C) Tm~(~C~ (J/gm) RAM 27,800 11,400 viscous oil ~ ---HSAM ~9,500 9,400 sernic~li~
HSAS 15,~00 8,700 sem~ d --- _ RAM:SA 10:9010,5007,200 72-76 86.18 98.59 2AM:SA '0:808,500 6,200 68-74 81.33 108.99 RAM:SA 30:7014,00010,800 68-70 79.33 103.02 R~M:SA 40:606,100 5,000 6S-70 76.63 65.~ 1 RAM:SA 50:50135,~001~,900 56-62 HSAM:SA 50:50 32,000 11,600 65-68 67.31 50.59 HSAS:SA 50:50 28,700 13,000 68-70 70.39 78.45 PSA 465,800 23,400 83 88.64 131.88 a Polymers s~ l,P i; r~ by melt con~ncq*~n b. ~elting poin~s d~,...no~ on an '~le.,llull.~---al melting yoin~ dy~d~u~
c. Melting ~qn ci n(~n ~ n ~ e dLh. --~ned by DSC.
d ~c ûf crystqllinity is obs~in~d from the ~H dLt,c...~ncd by DSC, Iqrger ~H values insinuate high~ degree of ~ystqllinity~
WO 961 2270 PCT~IB9~/00007 T~ 2. Oth-r c~r~ct-ri~tic~ of poly~-r~
rR. All polyme~s had typical IR p~aks at ~900, . 850. 1805, and 1740 cm-l.
1 H-N~IR of homopolymers of RAM,HSAM,HSAS, and 1: 1 copolymers wirh SA (d ppm):
PR~M: 6.~7 (dd, 2H, CO-CH=CH-CO), 5.43 (m, lH, CH=CH3, 5.31 (m, IH,CE~=CH), 4.96 (m, lH, methine), 2.47 (t, 2H when prepolymer is he~d-to-t3il, CH2-COO-), '.1~ (t, 'H
when prepolymcr is head-~o-head, CH2-COO-). 2.30 (m, 2H, CH=CH-CH2-CH2-), 2.00 (dd7 2H,CH-CH2-CH=CH), 1.60 (m, 4H, C~l2-cH2-cQQco- ~nd CH=CH-CQQ-CH-CH2-CH2), 1.29 (brd, 16H, aliphatic methylenes), 0.88 (t, 3H, CH2-CH3).
PHSAS: 4.88 (quintet, lH, methine3, 2.76 (t, 2H, COOC~CH2-CH2-COO-CH~, 2.64 (t, 2H, COOCO-CH2-CH2-COO-CH), 2.43 (t, 2H, CH2-cooco)~ 1.65 (m, 4H, CH2-CH-QCQ-CH2), 1.51 (brrm, 2H, CH2-CH2-COOCO), 1.25 (m, 2 'H, aliphatic me2h~!enes), 0.88 (t, 3H, CH2-CH3).
rHSAM: 6.30 (dd, 2H, CO-CH=CH-CO), 4.98 (quintct, IH, methine), '.52 (t, 'H ~vhen prepolymer is head-to-tail, CH2-COO-), 2.42 (t, 2H when prepolymer is head-to-head. CHq-COO-), 1.58 (m, 4H, CH2-CH2-COOCa and CH=CH-COaCH-C~12-CH~), 1.24 (brd, ~2H, ~lirh~*c methylenes), 0.83 (t, 3H, CH2-CH3).
P(RAM-SA)l:l: 6.~7 (s, 2H, CO-CH=CH-CO), 5.4S (brm,lH,COOCO-CH~-COO-CH), 5.33 (brm, lH, COOCO-CH=CH-COO-CH), 4.98 (brm, IH, methine), 2.53 ~t, 2H
whcn RAM pr~polymer is head-to-tail, CH2-COO ), 2.44 (t, 2H when RAM prepolymer is head-to-head, CH2-COO-), 2.35 (m, 2H, -o-cH-cH2-cH=cH-cH2-)~ 2.09 (dd, 2H.-O-CH-CH2-CH=CH-), 1.65 (m, 4H, C~I2-CH2-COOCO-andCH=CH-COaCH-CH2-CHL), 1.'~
and 1.25 (two brs, ~lirh~ti~ methylenes f~m RAM and from SA), 0.87 (t, 3H, CH2-CH3).
P(HSAS-SA)1:1: 4.88 (quintet, lH, methine), 2.77 (t, 2H, COOCO-CH2-CH2-COO-CH), 2.66 ~t, 2H, COOCO-CH2-CH2-COO-CH), 2.44 (t, 6H, CH2-COOCO), 1.65 ~m, 6H, CH2-CH-OCO CH2), 1.51 (brm, 4H, CH2-CH2-COOCO), 1.32 (m, 12H, CEI2-CH2-CH2-CH2-COO), 1.25 (m, ~lirh~*~ methylenes), 0.88 (t, 3H, CH2-CH3).
P(HSAM-SA)1:1: 6.30 (brm, 2H, CO-CH=CH-CO), 4.98 (brm, IH, meshine), '.~4 (t, CH2-COO-), 1.62 (tt, 2H, CH2-cH2-cooco-)~ 1.56 (dt, 4H, -cH2-co~cH-cH2-(CH2)4-CH3 and -CH2-COaCH-CII2-(CH2)9-COa),1.32 and 1.'5 (two brd. 31ipha~ic methylenes from HSAM and h~m SA),0.88 (t, 3H, CH2-CH3).
PCI'11b5S~00007 T~ 3. ~- :h-n~c~l prop~rti~ of f~tty ~ci~ polym~rs Polymer Mw Mn Tensile Compression co~"~ on Strength at b~
(~lP3) (%) P(RAM-SA)l:1135,'00 5,300 3.2 buclcled before b~e~ng P(HSAM-SA)l:l 4,300 2,100 2.7 22.95 P(HSAS-SA)1:1 9,400 3,300 2.5 20.91 P(FAD SA)I:173,000 5,900 5.7 9.75 PSA 18,600 5,800 7.~ 1.57 4 . D~t~ analy~i~ for ~iaci~ fat cont- ~ n~ n~
lacti~- copoly~-r~
Polymer: Viscosity Meltin~ point (dL ~) (oC) P(LA-RAM-PG!8:1:10.22 42~7 P(L9.-HSAM-PG)8:1:10.15 38-45 P(LA-HSAS-PG)8: 1:10.20 47-~0 CA 022l0800 l997-07-l7 W096122270 PCT/~S~007 ~ R~C~8 1. Domb et al., Polymeric Biomateria}s, NY (in press) 2. Domb et al., Polym. Adv. ~echnol. (in press) 3. Domb et al., Biopolymers (in press) 4. Leong et al., Biomed. Mat. Res, 19:941 (1985) 5. Domb and Maniar (1993) J. Polymer Sci.:Part A:Polymer Chem. 31:1275-1285 6. Domb and Langer ( 1987) J. Polym. Sci. Part A: Polym.
Chem., 1987, 25:3373 7. Ratacliffe et al. (1984) J. Pharm. Pharmacol. 36:431 8. Laurencin et al. (1990) J. Biomed. Mat. Res, 24:1463
Clean specimens (30 mg, 2x2x4 mm in size) of the following polymers:
1. poly(RAM-SA)30:70, 2. poly (HSAM - SA) 50: 50, 3. poly(HSAS-SA)50:50, 4. poly(FAD-SA)50:50, 5. Vicril (Ethicon), 6. poly(FAD-SA)50:50, and 7. poly(sebacic acid) {PSA}
WO 96S22270 PCT/lb551~0007 were implanted subcutaneously in four dorsal sites of male Sprague-Dawley rats (250-300 g). Six rats were used in the study and each rat was implanted randomly with four different specimens. All animal work was done under sterile conditions. The polymer specimens were dipped in 70% alcohol prior to insertion. The animals were sacrificed after 12 and 30 days post implantation, and the implantation sites were examined macroscopically and histologically. The polymer remnants were retrieved and analyzed.
Macroscopically, no swelling or pathological signs were observed in any of the groups during the experiment and at sacrifice. The animals appeared healthy and did not show any weight loss. The implantation sites were clean and normal without any swelling and the remnants of the implanted polymers were easily retrieved. At the implant site of the new polymers, a small amount of polymer remnants (30-40% of the original mass) in the form of a soft mass was seen. The animals implanted with poly(FAD-SA)50:50 had solid remnants in the site of about 70~ of the original implant size. About 20% of the PSA remained at the implant site after 12 days, and the Vicril polymer remained intact. Histopathology examination of tissue specimens from the area confined to the tissue in direct 2S contact with the polymer device showed mild inflammation which was rated 2 in a scale from 1 to 5 where: 1 -PCT111~3100007 resembles no irritation; 2 - slight inflammation; 3 -moderate; 4 - marked; and 5 - severe inflammation. No encapsulation was found with any of the samples.
A second group of rats which were implanted with the polymers under similar conditions were completely eliminated from the site after 12 weeks. In comparison, Vicril polymers remained almost intact, poly(FAD-sA)so:5o was only 60% eliminated.
This experiment indicates that the new fatty acid based polymers are biocompatible. The elimination time in vivo of these polymers is shorter than for the FAD-based polymers.
The rat model has been considered highly predictable of human response for toxicant elimination7 and biocompatibility. 8 5. In vitro hydrolysis. The hydrolysis of the l:1 copolymers with SA was studied by:
(a) weight loss of the sample;
(b) monitorinq the change of molecular weight by gel permeation chromatograph (GPC);
(c) monitoring the disappearance of the anhydride linkage and the formation of carboxylic acid by FTIR
spectroscopy; and (d) the release of sebacic acid from the polymer by HPLC analysis.
The hydrolysis studies were conducted in 0.1 M
phosphate buffer pH 7.4 at 37~C using rectangular samples 3x5x8 mm in size and weighing about 100-150 mg. The samples were taken out from the buffer at different time intervals and were weighed after being dried thoroughly in the oven. The percent weight loss of the sample and the transformation of the anhydride bond to acid as a function of time are shown in Figure 1. The change in molecular weight was monitored by GPC showing a drastic drop in molecular weight in the first 24 hours and then stabilized at about 6,000-7,000 from then on. The samples were observed visually for the changes in the external appearance. At any stage of the experiment, the samples did not crumble nor were there any cracks visible.
6. In vi~o ~n~ymat~c degradat~on. The enzymatic degradation of these new monomers were compared to those of the oligomerized fatty acids. The monomers RAM, HSAM, HSAS, FAD, and FAT (200 mg) were mixed in a solution containing esterase (2 ml, containing 50 units of esterase from porcine liver, Sigma Chemical Company, St.
Louis, Missouri) and were incubated for 24 hours at 37~C.
The monomers or their degradation products were extracted with chloroform and analyzed by lH NMR. The lH NMR spectra of the FAD and FAT monomers were identical before and after treatment. The RAM, and HSAS monomers contained about 10%
ricinoleic acid or 12-hydroxy stearic acid, respectively.
WO 96/22270 PCT/~5S,'0~û~7 This study demonstrates the biodegradability of the new monomers compared to the oligomerized fatty acid monomers.
7. In vitro drug r-leas-. Ciprofloxacin (5% by weight) was incorporated in rectangular tablets (3x5x8 mm in size and 200 mg weight) of poly(RAM-SA)l:l, P(HSAM:SA)l:l, P(HSAS:SA)l:l, P(FAD:SA)1:1 and poly(suberic anhydride) by the melt method. In vitro drug release was determined in phosphate buffer pH 7.4 at 37~C.
Ciprofloxacin concentration was determined by W detection at 272 nm. The results are shown in Figure 2. The drug release followed a first order kinetics (r2=0.89-0.99) with a fast release during the first lO days and a slow release thereafter.
In a second experiment, Ciprofloxacin (5% weight) was incorporated in rectangular tablets (3x5x8 mm in size and 20 mg weight) of poly(RAM-SA) of various compositions by the melt method. In vitro drug release was determined in phosphate buffer pH 7.4 at 37~C. Ciprofloxacin concentration was determined by W detection at 272 nm.
The results are shown in Figure 3. The drug release followed a first order kinetics (r2=0.96) with a fast release during the first 10 days and a slow release thereafter. The drug release rate was increased with the increase in the sebacic acid content in the polymer;
however, a small difference in the release profile was found for the polymers composed of 40 to 80% sebacic acid WC)96122270 PCT/lb9S~ ~7 (SA). Similar results were reported for the FAD-SA
copolymers.
The preparation of dimer oleic acid or dimer erucic acid (FAD) contains two steps. In the first step, oleic acid or erucic acid undergo a coupling reaction using clay as a catalyst. In the second step, the product is hydrogenated to saturate the double bonds in the product.
During the first step, many by-products are formed, including trimers and tetramers, that are difficult to remove. Also, the FAD product contains cyclic and aromatic by-products which counts to about 30% of the Priipol 1004 and lOo9 products which are the most available pure FAD
products (based on producer, Unicema, information). The product of the present invention contains only one component, the linear diacid monomer which is synthesized in a single esterification step (condensation reaction in general) which cannot form other oligomers or cyclic materials, but the linear diacid as described herein.
The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.
Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims the invention may be practiced otherwise than as specifically described.
PCTIIB9~/00007 W~ 96122270 T~ Mol-cul~r ~-~g~t~ ~nd th~ l ch~ract-r~ation o~ f~tty aci~ ~-t-r pol~-r~
Polym~r of Molecular weiBhtMel~ing pointb TmC ~d Mw Mn (~C) Tm~(~C~ (J/gm) RAM 27,800 11,400 viscous oil ~ ---HSAM ~9,500 9,400 sernic~li~
HSAS 15,~00 8,700 sem~ d --- _ RAM:SA 10:9010,5007,200 72-76 86.18 98.59 2AM:SA '0:808,500 6,200 68-74 81.33 108.99 RAM:SA 30:7014,00010,800 68-70 79.33 103.02 R~M:SA 40:606,100 5,000 6S-70 76.63 65.~ 1 RAM:SA 50:50135,~001~,900 56-62 HSAM:SA 50:50 32,000 11,600 65-68 67.31 50.59 HSAS:SA 50:50 28,700 13,000 68-70 70.39 78.45 PSA 465,800 23,400 83 88.64 131.88 a Polymers s~ l,P i; r~ by melt con~ncq*~n b. ~elting poin~s d~,...no~ on an '~le.,llull.~---al melting yoin~ dy~d~u~
c. Melting ~qn ci n(~n ~ n ~ e dLh. --~ned by DSC.
d ~c ûf crystqllinity is obs~in~d from the ~H dLt,c...~ncd by DSC, Iqrger ~H values insinuate high~ degree of ~ystqllinity~
WO 961 2270 PCT~IB9~/00007 T~ 2. Oth-r c~r~ct-ri~tic~ of poly~-r~
rR. All polyme~s had typical IR p~aks at ~900, . 850. 1805, and 1740 cm-l.
1 H-N~IR of homopolymers of RAM,HSAM,HSAS, and 1: 1 copolymers wirh SA (d ppm):
PR~M: 6.~7 (dd, 2H, CO-CH=CH-CO), 5.43 (m, lH, CH=CH3, 5.31 (m, IH,CE~=CH), 4.96 (m, lH, methine), 2.47 (t, 2H when prepolymer is he~d-to-t3il, CH2-COO-), '.1~ (t, 'H
when prepolymcr is head-~o-head, CH2-COO-). 2.30 (m, 2H, CH=CH-CH2-CH2-), 2.00 (dd7 2H,CH-CH2-CH=CH), 1.60 (m, 4H, C~l2-cH2-cQQco- ~nd CH=CH-CQQ-CH-CH2-CH2), 1.29 (brd, 16H, aliphatic methylenes), 0.88 (t, 3H, CH2-CH3).
PHSAS: 4.88 (quintet, lH, methine3, 2.76 (t, 2H, COOC~CH2-CH2-COO-CH~, 2.64 (t, 2H, COOCO-CH2-CH2-COO-CH), 2.43 (t, 2H, CH2-cooco)~ 1.65 (m, 4H, CH2-CH-QCQ-CH2), 1.51 (brrm, 2H, CH2-CH2-COOCO), 1.25 (m, 2 'H, aliphatic me2h~!enes), 0.88 (t, 3H, CH2-CH3).
rHSAM: 6.30 (dd, 2H, CO-CH=CH-CO), 4.98 (quintct, IH, methine), '.52 (t, 'H ~vhen prepolymer is head-to-tail, CH2-COO-), 2.42 (t, 2H when prepolymer is head-to-head. CHq-COO-), 1.58 (m, 4H, CH2-CH2-COOCa and CH=CH-COaCH-C~12-CH~), 1.24 (brd, ~2H, ~lirh~*c methylenes), 0.83 (t, 3H, CH2-CH3).
P(RAM-SA)l:l: 6.~7 (s, 2H, CO-CH=CH-CO), 5.4S (brm,lH,COOCO-CH~-COO-CH), 5.33 (brm, lH, COOCO-CH=CH-COO-CH), 4.98 (brm, IH, methine), 2.53 ~t, 2H
whcn RAM pr~polymer is head-to-tail, CH2-COO ), 2.44 (t, 2H when RAM prepolymer is head-to-head, CH2-COO-), 2.35 (m, 2H, -o-cH-cH2-cH=cH-cH2-)~ 2.09 (dd, 2H.-O-CH-CH2-CH=CH-), 1.65 (m, 4H, C~I2-CH2-COOCO-andCH=CH-COaCH-CH2-CHL), 1.'~
and 1.25 (two brs, ~lirh~ti~ methylenes f~m RAM and from SA), 0.87 (t, 3H, CH2-CH3).
P(HSAS-SA)1:1: 4.88 (quintet, lH, methine), 2.77 (t, 2H, COOCO-CH2-CH2-COO-CH), 2.66 ~t, 2H, COOCO-CH2-CH2-COO-CH), 2.44 (t, 6H, CH2-COOCO), 1.65 ~m, 6H, CH2-CH-OCO CH2), 1.51 (brm, 4H, CH2-CH2-COOCO), 1.32 (m, 12H, CEI2-CH2-CH2-CH2-COO), 1.25 (m, ~lirh~*~ methylenes), 0.88 (t, 3H, CH2-CH3).
P(HSAM-SA)1:1: 6.30 (brm, 2H, CO-CH=CH-CO), 4.98 (brm, IH, meshine), '.~4 (t, CH2-COO-), 1.62 (tt, 2H, CH2-cH2-cooco-)~ 1.56 (dt, 4H, -cH2-co~cH-cH2-(CH2)4-CH3 and -CH2-COaCH-CII2-(CH2)9-COa),1.32 and 1.'5 (two brd. 31ipha~ic methylenes from HSAM and h~m SA),0.88 (t, 3H, CH2-CH3).
PCI'11b5S~00007 T~ 3. ~- :h-n~c~l prop~rti~ of f~tty ~ci~ polym~rs Polymer Mw Mn Tensile Compression co~"~ on Strength at b~
(~lP3) (%) P(RAM-SA)l:1135,'00 5,300 3.2 buclcled before b~e~ng P(HSAM-SA)l:l 4,300 2,100 2.7 22.95 P(HSAS-SA)1:1 9,400 3,300 2.5 20.91 P(FAD SA)I:173,000 5,900 5.7 9.75 PSA 18,600 5,800 7.~ 1.57 4 . D~t~ analy~i~ for ~iaci~ fat cont- ~ n~ n~
lacti~- copoly~-r~
Polymer: Viscosity Meltin~ point (dL ~) (oC) P(LA-RAM-PG!8:1:10.22 42~7 P(L9.-HSAM-PG)8:1:10.15 38-45 P(LA-HSAS-PG)8: 1:10.20 47-~0 CA 022l0800 l997-07-l7 W096122270 PCT/~S~007 ~ R~C~8 1. Domb et al., Polymeric Biomateria}s, NY (in press) 2. Domb et al., Polym. Adv. ~echnol. (in press) 3. Domb et al., Biopolymers (in press) 4. Leong et al., Biomed. Mat. Res, 19:941 (1985) 5. Domb and Maniar (1993) J. Polymer Sci.:Part A:Polymer Chem. 31:1275-1285 6. Domb and Langer ( 1987) J. Polym. Sci. Part A: Polym.
Chem., 1987, 25:3373 7. Ratacliffe et al. (1984) J. Pharm. Pharmacol. 36:431 8. Laurencin et al. (1990) J. Biomed. Mat. Res, 24:1463
Claims (19)
1. A monomeric diacid derivative comprising at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond whereby said degradable bond degrades in a biological environment to form naturally occurring fatty acid products.
2. The hydrolytically or enzymatically degradable bond of claim 1 selected from the group consisting of ester, amide, urethane, urea and carbonate bonds.
3. The derivative of claim 1 having the structure wherein R, R1 and R2 are aliphatic organic residues with 0 to 20 carbon atoms and can be the same or different, X is an enzymatically or hydrolytically degradable bond.
4. The derivative of claim 1 derived from monoglyceride dicarboxylic acid and having the structure wherein x is an integer from 5 to 25; y is an integer from 1 to 12; and z includes the substitution groups CO, CO-O, CO-NH.
5. The derivative of claim 1 derived from tartaric acid and having the structure wherein x is an integer from 5 to 25 and Z includes the substitution groups CO, CO-O, CO-NH.
6. The derivative of claim 1 derived from a dicarboxylic acid fat and having the structure wherein y is an integer from 1 to 12; v+w are integers which total 25; and M includes the substitution groups O-CO, O-CO-O, O-CO-NH, O-PO2-O, NH-CO.
7. The derivative of claim 1 synthesized from ricinoleic acid and maleic anhydride forming ricinoleic acid maleate with the structure of
8. The derivative of claim 7 hydrogenolated to form 12-hydroxystearic acid succinate with the structure of
9. The derivative of claim 1 synthesized from the reaction between 12-hydroxystearic acid and maleic anhydride with the structure of
10. A polymer essentially consisting of repeating units of a monomeric diacid derivative comprising at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond whereby said degradable bond in a biological environment degrades forming naturally occurring fatty acid products.
11. The hydrolytically or enzymatically degradable bond of claim 10 selected from the group consisting of ester, amide, urethane, urea and carbonate bonds.
12. A drug release system comprising a pharmacologically effective amount of a drug and a polymer matrix essentially consisting of repeating units of a monomeric diacid derivative comprising at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond whereby said degradable bond in a biological environment degrades forming naturally occurring fatty acid products wherein said drug is entrapped within said matrix and releasable upon degradation of said degradable bond.
13. The hydrolytically or enzymatically degradable bond of claim 12 selected from the group consisting of ester, amide, urethane, urea and carbonate bonds.
14. A biocompatible, biodegradable, implantable material essentially consisting of repeating units of a monomeric diacid derivative comprising at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond whereby said degradable bond in a biological environment degrades forming naturally occurring fatty acid products.
15. The hydrolytically or enzymatically degradable bond of claim 14 selected from the group consisting of ester, amide, urethane, urea and carbonate bonds.
16. A method for synthesizing a biodegradable polymer containing hydrolyzable diacid fats comprising preparing at least one highly pure prepolymer of monomeric diacid derivative comprising at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond;
polymerizing at least one highly pure prepolymer at a temperature and reaction time to form a polyanhydride or polyester of an appropriate molecular weight; and stopping said polymerization when the appropriate molecular weight product is obtained.
polymerizing at least one highly pure prepolymer at a temperature and reaction time to form a polyanhydride or polyester of an appropriate molecular weight; and stopping said polymerization when the appropriate molecular weight product is obtained.
17. The method of claim 16 wherein a copolymer is formed from at least two highly pure prepolymers polymerized together.
18. A plasticizing diacid derivative comprising at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond whereby said degradable bond degrades in a biological environment to form naturally occurring fatty acid products.
19. The diacid derivative of claim 18 wherein the diacid derivative is based on ricinoleic acid maleate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002210800A CA2210800A1 (en) | 1995-01-18 | 1995-01-18 | Biopolymers derived from hydrolyzable diacid fats |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002210800A CA2210800A1 (en) | 1995-01-18 | 1995-01-18 | Biopolymers derived from hydrolyzable diacid fats |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2210800A1 true CA2210800A1 (en) | 1996-07-25 |
Family
ID=4161084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002210800A Abandoned CA2210800A1 (en) | 1995-01-18 | 1995-01-18 | Biopolymers derived from hydrolyzable diacid fats |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2210800A1 (en) |
-
1995
- 1995-01-18 CA CA002210800A patent/CA2210800A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Domb et al. | Absorbable biopolymers derived from dimer fatty acids | |
EP0260415B1 (en) | Synthesis and application of high molecular weight polyanhydrides | |
US4857311A (en) | Polyanhydrides with improved hydrolytic degradation properties | |
US6984393B2 (en) | Biodegradable elastomer and method of preparing same | |
Grijpma et al. | Preparation of biodegradable networks by photo-crosslinking lactide, ε-caprolactone and trimethylene carbonate-based oligomers functionalized with fumaric acid monoethyl ester | |
Kumar et al. | Polyanhydrides: an overview | |
Sathiskumar et al. | Synthesis, characterization, degradation of biodegradable castor oil based polyesters | |
JP3121604B2 (en) | Aromatic polyanhydride composition | |
Xue et al. | Biodegradable shape-memory block co-polymers for fast self-expandable stents | |
Heijkants et al. | Uncatalyzed synthesis, thermal and mechanical properties of polyurethanes based on poly (ε-caprolactone) and 1, 4-butane diisocyanate with uniform hard segment | |
US5968543A (en) | Polymers with controlled physical state and bioerodibility | |
Domb et al. | Biodegradable polymers derived from natural fatty acids | |
EP0258780B1 (en) | Polyesters containing alkylene oxide blocks as drug delivery systems | |
Li et al. | Synthesis, characteristics and in vitro degradation of star-block copolymers consisting of L-lactide, glycolide and branched multi-arm poly (ethylene oxide) | |
US5270419A (en) | Polyanhydrides of oligomerized unsaturated aliphatic acids | |
AU637883B2 (en) | Polyanhydrides of the oligomerized unsaturated aliphatic acids | |
US5473103A (en) | Biopolymers derived from hydrolyzable diacid fats | |
JP2002504939A (en) | Biodegradable polyester urethane, production method thereof and use thereof | |
US7674285B2 (en) | Polyanhydride polymers and their uses in biomedical devices | |
US20130331526A1 (en) | Temperature-sensitive polyethylene glycol / polyester block copolymer in which bioactive functional group is introduced into side chain thereof | |
EP1339776B1 (en) | Polyanhydrides | |
WO1996022270A1 (en) | Biopolymers derived from hydrolyzable diacid fats | |
Mao et al. | Biodegradable poly (terephthalate-co-phosphate) s: synthesis, characterization and drug-release properties | |
KR101455359B1 (en) | Polyester block copolymer having various functional groups in side chain or chain-end position of which mechanical strength and biodegradation period is adjustable | |
CA2210800A1 (en) | Biopolymers derived from hydrolyzable diacid fats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |